Thrombotic Thrombocytopenic Purpura News and Research

RSS
Nanobodies: unharnessed potential in COVID-19 treatment

Nanobodies: unharnessed potential in COVID-19 treatment

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Acute kidney injury on the rise in hospitalized pregnant women

Acute kidney injury on the rise in hospitalized pregnant women

Researchers find synergistic connection between two deadly blood-clotting diseases

Researchers find synergistic connection between two deadly blood-clotting diseases

First therapy indicated for treating adults with rare blood clotting disorder receives FDA approval

First therapy indicated for treating adults with rare blood clotting disorder receives FDA approval

Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder

Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Study points to potential treatment for thrombotic thrombocytopenic purpura

Study points to potential treatment for thrombotic thrombocytopenic purpura

New ASH report outlines several models for 'systems-based clinical hematologist'

New ASH report outlines several models for 'systems-based clinical hematologist'

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros announces financial results for second quarter of 2013

Omeros announces financial results for second quarter of 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Researchers identify link between immune response and blood clotting

Researchers identify link between immune response and blood clotting